Sai Life Sciences Ltd Stock Price Today (NSE: SAILIFE)

Sai Life Sciences Ltd

1315.100.10 (0.01%)
Market Closed

Fundamental Score

...

Sai Life Sciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Sai Life Sciences Ltd share price today is 1315.10, down 0.01% on NSE/BSE as of 31 July 2026. Sai Life Sciences Ltd (SAILIFE) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of 26.85K (Cr). The 52-week high for SAILIFE share price is 1338.00 and the 52-week low is 778.50. At a P/E ratio of 75.64x, SAILIFE is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 15.39% and a debt-to-equity ratio of 0.12.

Sai Life Sciences Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
1338.00
Low
1191.10
Volume
3.7L
Change
+5.73%

Sai Life Sciences Ltd share price chart: 5.73% return over the past month. 52-week high ₹1338.00, 52-week low ₹778.50.

Sai Life Sciences Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
1315.101338.001303.601315.103.01L (Cr)
1315.901320.001301.001315.203.20L (Cr)
1298.701320.701291.501315.903.91L (Cr)
1287.001305.501272.701300.503.91L (Cr)
1244.801295.001239.301287.004.77L (Cr)
1299.001299.001275.001288.703.11L (Cr)
1278.001299.901270.001297.003.11L (Cr)
1294.001294.001265.201272.002.01L (Cr)
1266.101300.001255.001294.905.90L (Cr)
1268.001292.001259.601268.804.00L (Cr)

Sai Life Sciences Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
1246.001338.001191.101315.10+5.55%
1175.001260.001109.201234.30+5.05%
1081.201184.80949.301160.00+7.29%
1000.001089.90927.051069.45+6.95%
992.501084.00938.00972.00-2.07%
847.701004.70783.85998.25+17.76%
905.00983.35791.10835.15-7.72%
890.00924.00845.60908.40+2.07%
917.80938.85846.05884.40-3.64%
860.50939.95839.25918.20+6.71%
829.80923.40821.10860.70+3.72%
795.20943.00778.50824.70+3.71%

Returns & Performance

Average

Return on Equity (ROE)

15.39%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

19.55%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

21.83%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Sai Life Sciences Ltd Valuation Check

Poor

Price to Earnings (P/E)

75.64x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Large-cap
Established & liquid; typically steadier returns.

Shareholding Pattern

Excellent

Promoter Holding

34.61%

% shares held by company founders/management

Excellent

FII Holding

21.17%

% shares held by foreign institutional investors

Excellent

DII Holding

31.54%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Good

Profit Growth (Quarterly YoY)

17.84%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

3.91%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

23.61%

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

42.17%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.12x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

13.08x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-9.62 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Sai Life Sciences Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of SAILIFE across key market metrics for learning purposes.

Positive Indicators

9 factors identified

Strong Return on Equity (15.39%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (19.55%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (21.83%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Consistent Growth Track Record (23.61% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Strong Profit Growth Track Record (42.17% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.12)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (13.08x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Strong Institutional Confidence (FII+DII: 52.71%)

Observation: Significant professional investor participation.

Analysis: High institutional holding often signals thorough due diligence.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

3 factors identified

Premium Valuation Risk (P/E: 75.64x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Negative Free Cash Flow (₹-9.62 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Sai Life Sciences Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Sai Life Sciences Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
44.9/100
1315
₹26845.66
75.6
Average
15.39%
Good
19.55%
Good
0.1
Excellent
42.17%
Excellent
23.61%
Excellent
0.00%
66.4/100
1991
₹468821.49
37.7
Average
15.95%
Good
20.53%
Excellent
0.1
Excellent
16.75%
Excellent
11.78%
Good
0.82%
56.3/100
8056
₹193163.97
73.6
Average
16.53%
Good
21.96%
Excellent
0.0
Excellent
5.71%
Good
8.67%
Good
0.41%
51.4/100
5123
₹169902.02
77.5
Average
27.43%
Excellent
15.19%
Good
1.8
Average
12.07%
Good
11.80%
Good
0.76%
Cipla Ltd...
CIPLA500087
40.2/100
1473
₹116131.81
30.5
Average
11.60%
Average
15.49%
Good
0.0
Excellent
9.94%
Good
8.01%
Good
0.90%
74.1/100
1078
₹115375.77
21.3
Average
21.25%
Excellent
21.14%
Excellent
0.5
Excellent
18.77%
Excellent
12.45%
Good
0.09%
Lupin Ltd...
LUPIN500257
83.4/100
2415
₹113976.53
20.0
Average
28.68%
Excellent
29.93%
Excellent
0.3
Excellent
37.02%
Excellent
13.02%
Good
0.72%
61.5/100
2470
₹105053.91
52.3
Average
13.12%
Average
13.50%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%
41/100
1148
₹102660.46
25.6
Average
11.22%
Average
13.04%
Average
0.2
Excellent
15.44%
Excellent
12.09%
Good
0.65%
24.6/100
1580
₹90035.87
25.4
Average
10.06%
Average
12.80%
Average
0.2
Excellent
0.80%
Average
6.32%
Good
0.26%
34.1/100
1816
₹84016.75
93.9
Average
18.30%
Good
17.76%
Good
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%

Sai Life Sciences Ltd PE Ratio History

Historical price-to-earnings ratio for SAILIFE — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20258.61₹908.40105.5x
FY 20243.98₹751.20188.7x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Sai Life Sciences Ltd Quarterly Performance

Latest quarterly metrics for SAILIFE — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

3.91%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

17.84%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

23.61%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

42.17%

Compounded annual net profit growth over 5 years

Sai Life Sciences Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for SAILIFE — calculated from daily price history

79RSI 14
Overbought — RSI 79

Momentum is strong — price may be stretched. Watch for pullbacks.

SMA 50
1215
▲ Price above SMA 50 — Short-term bullish
SMA 200
1004
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
421K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Sai Life Sciences Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Sai Life Sciences Ltd (SAILIFE) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Sai Life Sciences Ltd

About SAILIFE (Sai Life Sciences Ltd)

Sai Life Sciences Ltd is a globally recognized Contract Research, Development, and Manufacturing Organization deeply rooted in pharmaceutical innovation. From its strategic base in... Hyderabad, India, Sai Life Sciences propels the boundaries of drug discovery and development through a comprehensive suite of services. Their expertise spans the entire pharmaceutical lifecycle, providing customized solutions from initial target identification and lead optimization to advanced drug substance and drug product manufacturing. With a commitment to scientific excellence and agility, Sai Life Sciences partners with pharmaceutical and biotechnology companies of all sizes, accelerating their journeys toward bringing life-saving medications to market. SAILIFE distinguishes itself by integrating cutting-edge technologies and a highly skilled scientific workforce. Their capabilities encompass a wide spectrum of disciplines, including medicinal chemistry, process development, analytical research, and formulation development. This integrated approach allows for seamless transitions between different phases of drug development, ensuring efficiency and minimizing potential delays. Beyond its scientific prowess, Sai Life Sciences places a strong emphasis on regulatory compliance and quality assurance. This dedication ensures that every project adheres to the highest industry standards, providing clients with confidence in the integrity and reliability of their results. Sai Life Sciences operates on a foundation of collaboration and client-centricity. They forge strong partnerships with their clients, working as an extension of their own teams to achieve shared goals. Their focus is on delivering tailored solutions that meet the specific needs of each project, while constantly adapting to evolving market demands. By investing in state-of-the-art infrastructure and attracting top talent, Sai Life Sciences continues to solidify its position as a trusted partner in the global pharmaceutical industry, driving innovation and making a tangible difference in healthcare outcomes worldwide.

Company Details

Symbol:SAILIFE
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Dr. Ranga Raju Kanumuri
Executive Chairman
Mr. Krishnam Raju Kanumuri
CEO, MD & Executive Director
Mr. Sivaramakrishnan Chittor
CFO & Whole Time Director

SAILIFE Share Price: Frequently Asked Questions

What is the current share price of Sai Life Sciences Ltd?

Sai Life Sciences Ltd (SAILIFE) trades at ₹1315.10 on NSE and BSE. Market cap ₹26.85K (Cr). Educational data only.

What is the P/E ratio of Sai Life Sciences Ltd?

Sai Life Sciences Ltd has a P/E of 75.64x vs industry average 34.89x.

What is the Bull Run score for Sai Life Sciences Ltd?

Sai Life Sciences Ltd has a Bull Run score of 44.9/100 based on 25+ financial parameters.

Does Sai Life Sciences Ltd pay dividends?

Sai Life Sciences Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Sai Life Sciences Ltd?

Sai Life Sciences Ltd has ROE of 15.39%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Sai Life Sciences Ltd?

Sai Life Sciences Ltd has debt-to-equity of 0.12.

Is Sai Life Sciences Ltd a good investment?

Bull Run gives Sai Life Sciences Ltd a score of 44.9/100. This is not investment advice — consult a SEBI-registered advisor.